MCID: RNL018
MIFTS: 39

Renal Pelvis Carcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Renal Pelvis Carcinoma

MalaCards integrated aliases for Renal Pelvis Carcinoma:

Name: Renal Pelvis Carcinoma 12 15 17 74
Malignant Tumor of Renal Pelvis 12 74
Malignant Neoplasm of Renal Pelvis 12
Malignant Renal Pelvis Neoplasm 12
Carcinoma of Kidney Pelvis 12
Renal Pelvis Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4919
ICD9CM 36 189.1
NCIt 51 C6142 C7525
SNOMED-CT 69 93985007
ICD10 34 C65

Summaries for Renal Pelvis Carcinoma

MalaCards based summary : Renal Pelvis Carcinoma, also known as malignant tumor of renal pelvis, is related to renal pelvis adenocarcinoma and renal pelvis transitional cell carcinoma. An important gene associated with Renal Pelvis Carcinoma is MACC1 (MET Transcriptional Regulator MACC1), and among its related pathways/superpathways are Photodynamic therapy-induced HIF-1 survival signaling and HIF-2-alpha transcription factor network. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Renal Pelvis Carcinoma

Diseases related to Renal Pelvis Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 renal pelvis adenocarcinoma 31.3 HCK KRT19 KRT7 PAX8 SLC2A1
2 renal pelvis transitional cell carcinoma 10.4 KRT7 UPK3A
3 nephrogenic adenoma of urinary bladder 10.4 KRT7 PAX8
4 nephrogenic adenoma 10.4 KRT7 PAX8
5 bladder benign neoplasm 10.4 KRT7 PAX8
6 bile duct adenoma 10.4 KRT20 KRT7
7 cystic basal cell carcinoma 10.4 KRT20 KRT7
8 endosalpingiosis 10.4 KRT7 PAX8
9 seminal vesicle adenocarcinoma 10.4 KRT20 KRT7
10 sensory organ benign neoplasm 10.4 KRT7 PAX8
11 transverse colon cancer 10.4 KRT20 KRT7
12 appendix adenocarcinoma 10.4 KRT20 KRT7
13 malignant syringoma 10.4 KRT20 KRT7
14 vulvar disease 10.4 KRT7 UPK3A
15 papillary transitional carcinoma 10.4 KRT20 KRT7
16 eyelid carcinoma 10.4 KRT20 KRT7
17 endocervical carcinoma 10.4 KRT7 PAX8
18 krukenberg carcinoma 10.4 KRT20 KRT7
19 large intestine adenocarcinoma 10.4 KRT20 KRT7
20 linitis plastica 10.4 KRT20 KRT7
21 lung acinar adenocarcinoma 10.4 KRT20 KRT7
22 small cell carcinoma of the bladder 10.4 KRT20 KRT7
23 adenoid squamous cell carcinoma 10.4 KRT20 KRT7
24 intratubular embryonal carcinoma 10.4 KRT20 KRT7
25 bile duct cystadenocarcinoma 10.4 KRT20 KRT7
26 jejunal adenocarcinoma 10.4 KRT20 KRT7
27 ovarian mucinous adenocarcinoma 10.4 KRT20 KRT7
28 mucinous adenocarcinoma 10.4 KRT20 KRT7
29 thymus adenocarcinoma 10.4 KRT20 KRT7
30 appendix disease 10.4 KRT20 KRT7
31 gastric diffuse adenocarcinoma 10.4 KRT20 KRT7
32 meibomian cyst 10.4 KRT20 KRT7
33 bladder lymphoma 10.4 KRT20 KRT7
34 papillary serous adenocarcinoma 10.4 KRT20 KRT7
35 bladder adenocarcinoma 10.4 KRT20 KRT7
36 medulloepithelioma 10.4 KRT20 KRT7
37 glycogen-rich clear cell breast carcinoma 10.4 KRT20 KRT7
38 peritoneum cancer 10.4 KRT7 PAX8
39 rectum adenocarcinoma 10.3 KRT20 KRT7
40 kidney benign neoplasm 10.3 KRT7 PAX8
41 ceruminoma 10.3 KRT7 SLC2A1
42 paget disease, extramammary 10.3 KRT20 KRT7
43 mucinous bronchioloalveolar adenocarcinoma 10.3 KRT20 KRT7
44 ampulla of vater adenocarcinoma 10.3 KRT20 KRT7
45 lymphoepithelioma-like carcinoma 10.3 KRT20 KRT7
46 eccrine sweat gland neoplasm 10.3 KRT20 KRT7
47 dermoid cyst 10.3 KRT20 KRT7
48 rete testis neoplasm 10.3 KRT20 PAX8
49 infiltrative basal cell carcinoma 10.3 KRT20 KRT7
50 cystadenofibroma 10.3 KRT20 KRT7

Comorbidity relations with Renal Pelvis Carcinoma via Phenotypic Disease Network (PDN):


Bladder Cancer Deficiency Anemia
Hydronephrosis Prostatic Hypertrophy
Ureter, Cancer of

Graphical network of the top 20 diseases related to Renal Pelvis Carcinoma:



Diseases related to Renal Pelvis Carcinoma

Symptoms & Phenotypes for Renal Pelvis Carcinoma

GenomeRNAi Phenotypes related to Renal Pelvis Carcinoma according to GeneCards Suite gene sharing:

27 (show all 23)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.77 HCK
2 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.77 HCK
3 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.77 SLC2A1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.77 KRT19
5 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.77 SLC2A1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.77 SLC2A1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.77 PAX8
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.77 KRT19
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.77 SLC2A1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.77 KRT19
11 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.77 HCK
12 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.77 HCK
13 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.77 PAX8
14 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.77 PAX8
15 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.77 PAX8 SLC2A1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.77 HCK KRT19 PAX8 SLC2A1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.77 KRT19 PAX8
18 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.77 PAX8
19 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.77 HCK
20 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.77 SLC2A1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-90 9.77 SLC2A1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.77 PAX8
23 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.77 HCK

Drugs & Therapeutics for Renal Pelvis Carcinoma

Drugs for Renal Pelvis Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 441203 84093 2767
2
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
3
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
4
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3
6 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
7 Immunologic Factors Phase 3,Phase 1,Phase 2
8 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
9 Antimetabolites Phase 3,Phase 1,Phase 2
10 Anti-Infective Agents Phase 3,Phase 1,Phase 2
11 Antiviral Agents Phase 3,Phase 1,Phase 2
12 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
13 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
14 Antibodies Phase 3,Phase 2,Phase 1
15 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
16 Immunoglobulins Phase 3,Phase 2,Phase 1
17 Antimitotic Agents Phase 3,Phase 2,Phase 1
18 Mitomycins Phase 3,Phase 2
19 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
20 Alkylating Agents Phase 3,Phase 2
21 Immunoglobulin G Phase 3,Phase 1
22 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
23 Endothelial Growth Factors Phase 3,Phase 1
24 Mitogens Phase 3,Phase 1
25 Angiogenesis Modulating Agents Phase 3
26 Angiogenesis Inhibitors Phase 3
27
Vinblastine Approved Phase 2,Phase 1 865-21-4 13342 241903
28
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
29
tannic acid Approved Phase 2 1401-55-4
30
nivolumab Approved Phase 2,Phase 1 946414-94-4
31
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
32
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
33
Fluorouracil Approved Phase 2 51-21-8 3385
34
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
35
Carboplatin Approved Phase 2 41575-94-4 38904 10339178 498142
36
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
37
leucovorin Approved Phase 2 58-05-9 6006 143
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
39
Doxil Approved June 1999 Phase 2,Phase 1 31703
40 Analgesics Phase 1, Phase 2
41 Analgesics, Non-Narcotic Phase 1, Phase 2
42 Interleukin-2 Phase 1, Phase 2
43 Peripheral Nervous System Agents Phase 1, Phase 2
44 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
45 Protein Kinase Inhibitors Phase 2,Phase 1
46 Antibodies, Blocking Phase 2
47 tyrosine Phase 2
48 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
49 Halichondrin B Phase 2,Phase 1
50 Vitamin B Complex Phase 2

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study Active, not recruiting NCT02793128 Phase 3 MitoGel™ instillations
2 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
3 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
4 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
5 Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma Completed NCT01282463 Phase 2 Docetaxel
6 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2 AZD4877
7 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2 TRC105
8 Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) Recruiting NCT02459119 Phase 2 Regorafenib
9 Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor M6620 in Treating Patients With Metastatic Urothelial Cancer Recruiting NCT02567409 Phase 2 ATR Kinase Inhibitor M6620;Cisplatin;Gemcitabine Hydrochloride
10 Sitravatinib and Nivolumab in Urothelial Carcinoma Study Recruiting NCT03606174 Phase 2 Sitravatinib;Nivolumab
11 Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT03397394 Phase 2 Rucaparib
12 Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Recruiting NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
13 Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Recruiting NCT03617913 Phase 2 Avelumab;Cisplatin;Fluorouracil;Mitomycin
14 Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Active, not recruiting NCT02412670 Phase 2 Methotrexate;Vinblastine;Doxorubicin Hydrochloride;Cisplatin;Gemcitabine Hydrochloride;Carboplatin
15 A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function Active, not recruiting NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
16 Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Active, not recruiting NCT00749892 Phase 2 Erlotinib Hydrochloride
17 Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Active, not recruiting NCT00365157 Phase 1, Phase 2 Eribulin Mesylate
18 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Not yet recruiting NCT03513952 Phase 2 Atezolizumab
19 A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) Not yet recruiting NCT03824704 Phase 2 Rucaparib;Nivolumab
20 A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy Terminated NCT01234519 Phase 1, Phase 2 AEZS-108;AEZS-108 at MTD
21 DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Terminated NCT01353222 Phase 2
22 Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies Completed NCT01182168 Phase 1 gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
23 Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Completed NCT01844947 Phase 1 Vinflunine;Sorafenib
24 Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Recruiting NCT02437370 Phase 1 Pembrolizumab;Docetaxel;Gemcitabine Hydrochloride
25 Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery Recruiting NCT02812420 Phase 1
26 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
27 Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Active, not recruiting NCT02300610 Phase 1 Enzalutamide;Cisplatin;Gemcitabine
28 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Active, not recruiting NCT02443324 Phase 1 Ramucirumab;Pembrolizumab
29 Optical Biopsy to Improve the Diagnosis of Kidney Cancer Unknown status NCT02073110
30 Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) Completed NCT01138124 Gabapentin prescriptions
31 Cancer in Patients With Gabapentin (GPRD) Completed NCT01236053 Gabapentin prescriptions
32 Familial and Atypical Urothelial Cancer Registry Recruiting NCT00902590
33 Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors Recruiting NCT03662204
34 Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer Recruiting NCT01050504

Search NIH Clinical Center for Renal Pelvis Carcinoma

Genetic Tests for Renal Pelvis Carcinoma

Anatomical Context for Renal Pelvis Carcinoma

MalaCards organs/tissues related to Renal Pelvis Carcinoma:

42
Kidney, Endothelial, Prostate, Colon

Publications for Renal Pelvis Carcinoma

Articles related to Renal Pelvis Carcinoma:

# Title Authors Year
1
Renal Pelvis Carcinoma with Renal Vein or Inferior Vena Cava Involvement Linked to Early-onset Lung Metastasis Based on CT Scan Diagnosis. ( 29715161 )
2018
2
Pre-therapy CT scan showing peritoneal thickening from metastatic renal pelvis carcinoma patients. ( 30116986 )
2018
3
Port-site metastasis as a primary complication following retroperitoneal laparoscopic radical resection of renal pelvis carcinoma or nephron-sparing surgery: A report of three cases and review of the literature. ( 27313720 )
2016
4
Metastasis-associated in colon cancer 1 is a novel survival-related biomarker for human patients with renal pelvis carcinoma. ( 24949951 )
2014
5
Renal oncocytoma and renal pelvis carcinoma: a rare coexistence of double renal tumors. ( 7801215 )
1994
6
Low dose epirubicin for hypercalcemia associated with renal pelvis carcinoma. ( 1712187 )
1991

Variations for Renal Pelvis Carcinoma

Expression for Renal Pelvis Carcinoma

Search GEO for disease gene expression data for Renal Pelvis Carcinoma.

Pathways for Renal Pelvis Carcinoma

Pathways related to Renal Pelvis Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.89 SLC2A1 VEGFA
2 10.79 SLC2A1 VEGFA
3 10.66 HCK UCHL1
4 10.61 CA9 SLC2A1 VEGFA
5 10.37 HCK VEGFA

GO Terms for Renal Pelvis Carcinoma

Cellular components related to Renal Pelvis Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 8.8 KRT19 KRT20 KRT7

Biological processes related to Renal Pelvis Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.5 KRT19 KRT20 KRT7
2 mesoderm development GO:0007498 9.37 HCK VEGFA
3 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.26 CA9 VEGFA
4 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.16 PAX8 VEGFA
5 kidney development GO:0001822 9.13 PAX8 UPK3A VEGFA
6 cornification GO:0070268 8.8 KRT19 KRT20 KRT7

Molecular functions related to Renal Pelvis Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.4 CA9 CSN3 GOLPH3 HCK KRT19 KRT20

Sources for Renal Pelvis Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....